Literature DB >> 17707827

Differential diagnosis in chronic lymphocytic leukaemia.

Estella Matutes1, Andrew Wotherspoon, Daniel Catovsky.   

Abstract

The diagnosis of chronic lymphocytic leukaemia (CLL) is based on clinical and laboratory features. Morphology and immunophenotype are the key initial diagnostic tests. In cases with atypical features, these investigations should be complemented with cytogenetics and/or histology to confirm the diagnosis and to exclude other B-cell disorders. Morphologically, CLL can be classified into typical and atypical forms. Cell-marker studies provide a robust foundation to establish the diagnosis as the lymphocytes have a distinct immunophenotypic signature. Although no single antigen is exclusively expressed in CLL cells, when several markers are compounded into a scoring system the results allow firming up of the diagnosis. Other immunological markers, such as CD38 or ZAP-70, have an important prognostic impact. Fluorescence in-situ hybridization (FISH) analysis also provides prognostic information, chiefly by detecting 17 (p53 locus) and 11q deletion, and may determine the type of therapy.

Entities:  

Mesh:

Year:  2007        PMID: 17707827     DOI: 10.1016/j.beha.2007.03.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  5 in total

1.  Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

Authors:  Sarah E M Herman; Amber L Gordon; Erin Hertlein; Asha Ramanunni; Xiaoli Zhang; Samantha Jaglowski; Joseph Flynn; Jeffrey Jones; Kristie A Blum; Joseph J Buggy; Ahmed Hamdy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

2.  Ligand-Guided Selection of Target-Specific Aptamers: A Screening Technology for Identifying Specific Aptamers Against Cell-Surface Proteins.

Authors:  Hasan E Zumrut; Mst Naznin Ara; Maria Fraile; George Maio; Prabodhika Mallikaratchy
Journal:  Nucleic Acid Ther       Date:  2016-05-05       Impact factor: 5.486

3.  The potential differential diagnosis value and clinical significance of CD35 expression in B-chronic lymphoproliferative disorders.

Authors:  Yu Shi; Lu Liu; Hui Yang; Xiao Chen; Yan Wang; Sishu Zhao; Huimin Jin; Yujie Wu
Journal:  Ann Transl Med       Date:  2021-07

4.  Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotyping.

Authors:  E S Costa; C E Pedreira; S Barrena; Q Lecrevisse; J Flores; S Quijano; J Almeida; M del Carmen García-Macias; S Bottcher; J J M Van Dongen; A Orfao
Journal:  Leukemia       Date:  2010-09-16       Impact factor: 11.528

5.  Evaluation of Caspase-9b and PP2Acα2 as potential biomarkers for chronic lymphocytic leukemia.

Authors:  Leticia Domínguez-Berrocal; Xiguang Zhang; Jean Marc Zini; Jesús Fominaya; Angelita Rebollo; Jerónimo Bravo
Journal:  Biomark Res       Date:  2016-05-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.